A phase 2 study of vatalanib in metastatic melanoma patients.
BACKGROUND
A phase 2 study of vatalanib (PTK787/ZK222584) an oral tyrosine kinase inhibitor of VEGFR 1, 2 and 3 was undertaken in patients with metastatic melanoma.


METHODS
Adults with pathologically confirmed metastatic melanoma, WHO Performance status 0-2, and adequate haematological, hepatic and renal function, were treated with vatalanib until disease progression. The trial used Fleming's single stage design.


RESULTS
Tumour control rate (CR+PR+SD) was 35% at 16 weeks, with objective response seen in only 1 patient. Median progression-free survival was 1.8 months (95% CI 1.8-3.7 months) and median overall survival was 6.5 months (95% CI 3.9-10.2 months).


CONCLUSIONS
Vatalanib stabilised disease in a proportion of patients, although overall survival was disappointing.
Cook
Natalie
N
Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK.
Basu
Bristi
B
Biswas
Swethajit
S
Kareclas
Paula
P
Mann
Colette
C
Palmer
Cheryl
C
Thomas
Anne
A
Nicholson
Steve
S
Morgan
Bruno
B
Lomas
David
D
Sirohi
Bhawna
B
Mander
Adrian P
AP
Middleton
Mark
M
Corrie
Pippa G
PG
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D010793:Phthalazines / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D010793:Phthalazines; D011725:Pyridines; C404768:vatalanib